Holen Sie sich die Stockscreener-App
0.858
56.86%
0.311
Handel nachbörslich:
.79
-0.068
-7.93%
Schlusskurs vom Vortag:
$0.547
Offen:
$0.5622
24-Stunden-Volumen:
9.19M
Relative Volume:
5.81
Marktkapitalisierung:
$61.01M
Einnahmen:
$391.70K
Nettoeinkommen (Verlust:
$-52.34M
KGV:
-1.144
EPS:
-0.75
Netto-Cashflow:
$-45.92M
1W Leistung:
+68.17%
1M Leistung:
+111.85%
6M Leistung:
+32.88%
1J Leistung:
-2.32%
1-Tages-Spanne:
$0.55
$0.8686
1-Wochen-Bereich:
$0.50
$0.8686
52-Wochen-Spanne:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Firmenname
Ovid Therapeutics Inc
Sektor
Branche
Telefon
212-776-4381
Adresse
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Vergleichen Sie OVID mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
0.858 | 38.90M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-06-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-05 | Eingeleitet | Wedbush | Outperform |
| 2023-12-21 | Eingeleitet | BTIG Research | Buy |
| 2023-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2021-04-20 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Ovid Therapeutics: Navigating the Maze of Rare Disease Innovation and Financial Constraints - AInvest
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - TipRanks
Ovid Therapeutics Reports Business Updates and Second Quarter 20 - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - Stock Titan
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating - Investing.com
Tools to monitor Ovid Therapeutics Inc. recovery probabilityShort-Term Growth Watch with Signal Prediction - Newser
Is Ovid Therapeutics Inc. stock poised for growthFree Watchlist for Low Risk High Return - Newser
Ovid Therapeutics OVID 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi. - AInvest
How to track smart money flows in Ovid Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating - Investing.com Australia
Has Ovid Therapeutics Inc. formed a bullish divergenceYield Curve Outlook and Long-Term Implication Summary - Newser
Short interest data insights for Ovid Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Ovid Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What are analysts’ price targets for Ovid Therapeutics Inc. in the next 12 monthsUnlock powerful trading signals and alerts - Jammu Links News
Is it the right time to buy Ovid Therapeutics Inc. stockOutstanding capital growth - Jammu Links News
Does Ovid Therapeutics Inc. stock perform well during market downturnsAchieve rapid wealth accumulation with smart picks - Jammu Links News
What makes Ovid Therapeutics Inc. stock price move sharplyGet real-time alerts on high-potential stocks - Jammu Links News
Is Ovid Therapeutics Inc. stock overvalued or undervaluedTremendous financial leverage - jammulinksnews.com
Should I hold or sell Ovid Therapeutics Inc. stock in 2025Invest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Ovid Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
How strong is Ovid Therapeutics Inc. company’s balance sheetMaximize gains with strategic stock entries - Jammu Links News
How does Ovid Therapeutics Inc. compare to its industry peersFree Wealth Planning Blueprint - Jammu Links News
Why is Ovid Therapeutics Inc. stock attracting strong analyst attentionSuperior stock growth - Jammu Links News
What is the dividend policy of Ovid Therapeutics Inc. stockUnrivaled growth potential - Jammu Links News
What are the technical indicators suggesting about Ovid Therapeutics Inc.Take advantage of unprecedented market momentum - Jammu Links News
Will Ovid Therapeutics Inc. price bounce be sustainableFree Fast Gaining Stock Screener Report - Newser
Is Ovid Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
What technical models suggest about Ovid Therapeutics Inc.’s comebackHigh Accuracy Trade Setup Identification - Newser
Ovid Therapeutics Inc (OVID) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Multi asset correlation models including Ovid Therapeutics Inc.Free Secure Capital Picks With Upside Potential - Newser
Combining price and volume data for Ovid Therapeutics Inc.Buy Strategy with Smart Exit Timing - Newser
Identifying reversal signals in Ovid Therapeutics Inc.Low Volatility Stock Analysis With Confidence - Newser
Why Ovid Therapeutics Inc. stock attracts strong analyst attentionBear Market Safe Zone Technical Analysis - Newser
Quantitative breakdown of Ovid Therapeutics Inc. recent moveDaily Exit and Entry Price Prediction - Newser
Ovid Therapeutics Inc. Stock Support and Resistance Levels You Should KnowWeekly Gain Forecast with Momentum Indicators - Newser
Published on: 2025-07-30 02:43:14 - beatles.ru
Institutional Tools Highlight Unusual Flow in Ovid Therapeutics Inc.Breakout Momentum Picks With Protection Outlined - metal.it
Analyzing Ovid Therapeutics Inc. with multi timeframe chartsConsistent Profit Signals with AI Models - Newser
Finanzdaten der Ovid Therapeutics Inc-Aktie (OVID)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):